FDA — authorised 21 October 2022
- Application: BLA761289
- Marketing authorisation holder: ASTRAZENECA AB
- Local brand name: IMJUDO
- Indication: INJECTABLE — INTRAVENOUS
- Status: approved
🇺🇸 IMJUDO in United States
FDA authorised IMJUDO on 21 October 2022
Marketing authorisations
FDA — authorised 10 November 2022
- Application: BLA761270
- Marketing authorisation holder: ASTRAZENECA AB
- Local brand name: IMJUDO
- Indication: INJECTABLE — INTRAVENOUS
- Status: approved
FDA
- Status: approved
IMJUDO in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is IMJUDO approved in United States?
Yes. FDA authorised it on 21 October 2022; FDA authorised it on 10 November 2022; FDA has authorised it.
Who is the marketing authorisation holder for IMJUDO in United States?
ASTRAZENECA AB holds the US marketing authorisation.